[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[3] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[4] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[5] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[6] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[7] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
[8] |
SU Xinxin, ZHAO Xiaoxiao, XIE Yanming.
Real-world analysis of combined administration of elemene emulsion injection in patients with liver cancer
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 929-934.
|
[9] |
HUANG Yanli, XIE Yanming, WANG Lianxin, SUN Linxi, LIU Huan, ZHUANG Yunni.
Clinical applications of Ciwujia injection in elderly patients in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 935-939.
|
[10] |
ZHANG Hongwei, LI Yuanyuan, XIE Yanming, MA Xiaochang, WANG Lianxin, WEI Ruili, SUN Linxi, XU Hongyan, ZHUANG Yan.
The drug combination of Danshen Ligustrazine injection in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 851-856.
|
[11] |
LIU Chang, LIN Huijun, SHEN Hongxia, YAN Meixing.
Analysis of Adverse drug reactions of intravenous medication in pediatric inpatients in a tertiary children's hospital
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 762-766.
|
[12] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
|
[13] |
BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong.
Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.
|
[14] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.
|
[15] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|